Format

Send to

Choose Destination
Lung Cancer. 2016 Feb;92:47-52. doi: 10.1016/j.lungcan.2015.12.003. Epub 2015 Dec 17.

Relationship between the consolidation to maximum tumor diameter ratio and outcomes following stereotactic body radiotherapy for stage I non-small-cell lung cancer.

Author information

1
Radiation Oncology Department, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: yuichiro.tsurugai@jfcr.or.jp.
2
Radiation Oncology Department, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
3
Clinical Trial Department, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.

Abstract

PURPOSE:

We investigated whether the ratio of the maximum diameter of consolidation to the maximum tumor diameter (consolidation/tumor ratio, CTR) predicted the outcomes of patients who received stereotactic body radiotherapy (SBRT) for non-small-cell lung cancer (NSCLC).

METHODS AND MATERIALS:

Between 2005 and 2014, 237 patients with stage I NSCLC were treated with SBRT, receiving 48 Gy in 4 fractions. Of these patients, those who received pretreatment thin section computed tomography were selected for this analysis. The relationship between the CTR and outcomes (local control [LC], disease-free survival [DFS], and overall survival [OS]) was analyzed.

RESULTS:

One hundred and fifty-five patients were eligible. The median follow-up time was 34.7 months (range, 1.2-109.8). In the CTR<0.5, CTR 0.5-<1, and CTR=1 groups, 0, 2, and 12 patients experienced local recurrences, respectively. Three-year DFS and OS rates were 96.7% and 87.5% in the CTR<0.5 group, 85.1% and 81.1% in the CTR 0.5-<1 group, and 63.3% and 70.1% in the CTR=1 group, respectively. In multivariate analysis, CTR was the only significant predictor of DFS (P<0.001).

CONCLUSION:

The CTR effectively predicts DFS after SBRT in NSCLC patients.

KEYWORDS:

Consolidation/tumor ratio; Ground-glass opacity; Non-small cell lung cancer; Stereotactic body radiotherapy

PMID:
26775596
DOI:
10.1016/j.lungcan.2015.12.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center